Designing a combined liothyronine (LT3), L- thyroxine (LT4) trial in symptomatic hypothyroid subjects on LT4 - the importance of patient selection, choice of LT3 and trial design

Overview of attention for article published in Frontiers in endocrinology, November 2023

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (71st percentile)
High Attention Score compared to outputs of the same age and source (94th percentile)

Mentioned by

twitter: 8 X users

Readers on

mendeley: 3 Mendeley

Summary X

So far, Altmetric has seen 9 X posts from 8 X users, with an upper bound of 44,193 followers.

@KatieLUFC @jeffreydachmd Perhaps he needs to keep up with the research? https://t.co/bpJmu18DVI

12 Jan 2024

Reply Repost Favourite

RT @AutoimmuneList: Designing a combined liothyronine (LT3), L- thyroxine (LT4) trial in symptomatic hypothyroid subjects on LT4 - the impo…

04 Dec 2023

Reply Repost Favourite

Designing a combined liothyronine (LT3), L- thyroxine (LT4) trial in symptomatic hypothyroid subjects on LT4 - the importance of patient selection, choice of LT3 and trial design https://t.co/nmcRLYFDKK https://t.co/yGKqPIM9BF

04 Dec 2023

Reply Repost Favourite

RT @MaryS58459511: Design of trials for T3 use for #hypothyroid patients who remain symptomatic on T4.

17 Nov 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 5 additional X posts.